In accordance with the UK’s NED (National Endoscopy Database), an average of about 35,478 endoscopy procedures were conducted per week by around 3007 endoscopists, which signifies 12 procedures per endoscopist.
The overall process of Endoscopy began as a gastrointestinal (GI) diagnosis method, and it has become a significant treatment method for GI pathologies in recent times. The device or the equipment has been in constant evolution since the implementation of the electric lamp, the coming of the flexible endoscopes, the recent development of robotic methods and the incorporation of ultrasonography.
Endoscopic devices or the instruments had already been utilized for the bladder, urethra, and uterine cervix. However, in 1868, it was Adolf Kussmaul who had performed the 1st direct esophagogastroscopy. After attending a sword-swallower performance, he had demonstrated that it was possible to launch a rigid tube to the stomach if the neck and head hyperextended, though without any sufficient illumination. Joseph Leiter, in the year 1882, had included an electrical lamp on the extreme tip of the endoscope.
In 2020, the overall valuation of the Global Robotic Endoscopy Devices Market was around USD 1.40 billion. It is anticipated to reach around USD 5.49 billion by 2030, representing an overall CAGR of 14.65 percent throughout the forecasted period.
Recent Developments in the Robotic Endoscopy Devices Market
Olympus Corporation (Japan) had paid an overall sum of USD 300 million in the month of May 2021 for Medi-Tate Ltd. (Israel), which had offered Olympus in-office therapy for benign prostatic hyperplasia (BPH) to extend its business line in-office treatment for the treatment of benign prostatic hyperplasia and to solidify its entire position as a leader in the domain of urological devices.